These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 25973680)
1. RGD-modifided oncolytic adenovirus exhibited potent cytotoxic effect on CAR-negative bladder cancer-initiating cells. Yang Y; Xu H; Shen J; Yang Y; Wu S; Xiao J; Xu Y; Liu XY; Chu L Cell Death Dis; 2015 May; 6(5):e1760. PubMed ID: 25973680 [TBL] [Abstract][Full Text] [Related]
2. Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus. Yang Y; Xu H; Huang W; Ding M; Xiao J; Yang D; Li H; Liu XY; Chu L J Cell Mol Med; 2015 May; 19(5):915-23. PubMed ID: 25683371 [TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor efficacy of integrin-targeted oncolytic adenovirus AxdAdB3-F/RGD on bladder cancer. Wang H; Cai Z; Yang F; Luo J; Satoh M; Arai Y; Li D Urology; 2014 Feb; 83(2):508.e13-9. PubMed ID: 24315309 [TBL] [Abstract][Full Text] [Related]
4. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers. Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007 [TBL] [Abstract][Full Text] [Related]
5. Gene therapy in colon cancer cells with a fiber-modified adenovector expressing the TRAIL gene driven by the hTERT promoter. Jacob D; Bahra M; Schumacher G; Neuhaus P; Fang B Anticancer Res; 2004; 24(5A):3075-9. PubMed ID: 15517918 [TBL] [Abstract][Full Text] [Related]
6. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route. Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824 [TBL] [Abstract][Full Text] [Related]
7. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus. Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242 [TBL] [Abstract][Full Text] [Related]
8. [Adenoviral vector expressing the TRAIL gene driven by the hTERT promoter]. Jacob D; Davis J; Schumacher G; Bahra M; Neuhaus P; Fang B Z Gastroenterol; 2004 Dec; 42(12):1363-70. PubMed ID: 15592959 [TBL] [Abstract][Full Text] [Related]
9. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Lamfers ML; Grill J; Dirven CM; Van Beusechem VW; Geoerger B; Van Den Berg J; Alemany R; Fueyo J; Curiel DT; Vassal G; Pinedo HM; Vandertop WP; Gerritsen WR Cancer Res; 2002 Oct; 62(20):5736-42. PubMed ID: 12384532 [TBL] [Abstract][Full Text] [Related]
10. Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells. Mao L; Yang C; Li L; Nai L; Fan L; Wang J; Li W; Wen R; Chen J; Zheng J Tumour Biol; 2014 Jun; 35(6):5937-44. PubMed ID: 24604329 [TBL] [Abstract][Full Text] [Related]
11. Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells. Liu Y; Chen L; Gong Z; Shen L; Kao C; Hock JM; Sun L; Li X Oncotarget; 2015 Feb; 6(5):3055-70. PubMed ID: 25605010 [TBL] [Abstract][Full Text] [Related]
12. Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer. Zhang Z; Huang Y; Newman K; Gu J; Zhang X; Wu H; Zhao M; Xianyu Z; Liu X Clin Cancer Res; 2009 Aug; 15(16):5154-60. PubMed ID: 19671855 [TBL] [Abstract][Full Text] [Related]
13. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma. Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790 [TBL] [Abstract][Full Text] [Related]
14. Fiber-modified adenovirus-mediated suicide gene therapy can efficiently eliminate bladder cancer cells in vitro and in vivo. Wang DG; Zhao MJ; Liu YQ; Liu XW; Niu HT; Song YF; Tian YX Oncotarget; 2016 Nov; 7(44):71710-71717. PubMed ID: 27687590 [TBL] [Abstract][Full Text] [Related]
15. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL. Liu X; Cao X; Wei R; Cai Y; Li H; Gui J; Zhong D; Liu XY; Huang K Cancer Gene Ther; 2012 Jan; 19(1):49-57. PubMed ID: 21979578 [TBL] [Abstract][Full Text] [Related]
16. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model. El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307 [TBL] [Abstract][Full Text] [Related]
17. Improved gene transfer into bladder cancer cells using adenovirus vector containing RGD motif. Hiwasa K; Nagaya H; Terao S; Acharya B; Hamada K; Mizuguchi H; Gotoh A Anticancer Res; 2012 Aug; 32(8):3137-40. PubMed ID: 22843884 [TBL] [Abstract][Full Text] [Related]
18. Arg-Gly-Asp (RGD)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in Mice. Shen YH; Yang F; Wang H; Cai ZJ; Xu YP; Zhao A; Su Y; Zhang G; Zhu SX PLoS One; 2016; 11(1):e0147173. PubMed ID: 26799485 [TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer. Zhai Z; Wang Z; Fu S; Lu J; Wang F; Li R; Zhang H; Li S; Hou Z; Wang H; Rodriguez R Gene Ther; 2012 Nov; 19(11):1065-74. PubMed ID: 22218302 [TBL] [Abstract][Full Text] [Related]
20. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]